Here is what I am reading into the acme trial and I am wondering what everyone thinks. The primary end point was a delta of 15 over placebo at day 84. The larger dose, at day 42 showed a delta of 6 (19 - 13), and the delta of 6 maintained up to day 84. The lower dose had absolutely no effect. This result could mean that the acme is il1b related but the drug is not very efficacious, and at the dose that it did show some efficacy, the effects were primarily early and did not last. I would like to see this trial continue beyond 3 months to see if there is any time the effects will be back in par with placebo. This is a quick and dirty way to #$%$ wether to just abandon this drug before they waist any more time and money on it and just let their partner do the research on the eye disease and if there is a success there then come back to it. The other drugs in their portfolio are a lot more promising than this and the cost of getting additional financing dollars have been dear.